This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 12 for:    Spinal Stabilization technologies
Previous Study | Return to List | Next Study

"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2) (LOPAIN2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05508360
Recruitment Status : Recruiting
First Posted : August 19, 2022
Last Update Posted : February 10, 2023
Sponsor:
Information provided by (Responsible Party):
Spinal Stabilization Technologies

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will be a prospective, open-label, multi-center study including 72 patients that will collect additional safety and efficacy data for the Spinal Stabilization Technologies PerQdisc Nucleus Replacement System.

Condition or disease Intervention/treatment Phase
Degenerative Disc Disease Chronic Low-back Pain Device: PerQdisc Nucleus Replacement System Not Applicable

Detailed Description:
This study will be a prospective, open-label, multi-center study that will collect additional safety and efficacy data for the minimally invasive PerQdisc Nucleus Replacement Device (NRD). Patients will have degenerative disc disease (DDD) in one or more lumbar discs. The NRD is used for surgical replacement of a single nucleus pulposus between spinal lumbar discs L1-S1 using an anterior or lateral transpsoas approach. Currently the surgical gold standard involves spinal fusion of the affected vertebral bodies, reducing range of motion and increasing stress on other vertebral bodies. The goal of nucleus replacement is to reduce chronic low back pain by maintaining disc height while preserving range of motion.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is an open-label study. Patients will receive one implant if they meet all inclusion/exclusion criteria after a review by the Medical Advisory Board (MAB).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: "Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2)
Actual Study Start Date : August 22, 2022
Estimated Primary Completion Date : August 22, 2024
Estimated Study Completion Date : August 22, 2029

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Lumbar Disc Nucleus Replacement
All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
 Device: PerQdisc Nucleus Replacement System
Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Perfromance: ODI [ Time Frame: 6 months ]
    Change in in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient-reported outcome tool

  2. Perfromance: ODI [ Time Frame: 12 months ]
    Change in in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient-reported outcome tool

  3. Performance: VAS [ Time Frame: 6 months ]
    Change in back pain as measured by the 100 - millimeter Visual Analog Scale (VAS)

  4. Performance: VAS [ Time Frame: 12 months ]
    Change in back pain as measured by the 100 - millimeter Visual Analog Scale (VAS)

  5. Safety: Expulsion & Device Failure [ Time Frame: 6 months ]
    Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's

  6. Safety: Expulsion & Device Failure [ Time Frame: 12 months ]
    Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's


Secondary Outcome Measures :
  1. Safety: Revision Surgery [ Time Frame: 6 months, 12 months, and 5 years ]
    Incidence of revision surgery

  2. Safety: Expulsion & Device Failure [ Time Frame: 5 years ]
    Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's

  3. Performance: Disc Height [ Time Frame: 6 months, 12 months, and 5 years ]
    Preservation of intervertebral disc height (in mm) as measured on MRI post-surgery compared to baseline

  4. Performance: RoM [ Time Frame: 6 months, 12 months, 5 years ]
    Preservation of range of movement (expressed in degrees) at the index and adjacent levels at baseline compared to follow-up using flexion/extension radiographs

  5. Safety: Neurological Status [ Time Frame: 6 months, 12 months, and 5 years ]
    Maintenance of baseline neurologic status through physical assessment evaluating nerve compression at baseline and post-surgical follow-up using pain, motor strength, and sensation feedback from the patient on a 0 (no compression) to 5 (major compression) scale

  6. Performance: Analgesic Score [ Time Frame: 6 months, 12 months, and 5 years ]
    Change in level of pain medication used comparing baseline to follow up visits based on a medication scale ranging from 0 (no meds) - 4 (high dose opioids)

  7. Safety: SAE [ Time Frame: 6 months, 12 months, and 5 years ]
    Incidence of serious adverse events that are related to the surgical procedure or Incidence of Serious Adverse Events related to the surgical procedure or device


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is skeletally mature and at least 21 years of age.
  • Patient has Degenerative Disc Disease (DDD) at one or more levels between L1 and S1 but the discogenic pain must be limited to a single level.
  • Patient has adequate disc height (6mm) at the level to be treated
  • Patient is not responsive to conservative, non-surgical treatment for back pain.
  • Patient has signed the approved Informed Consent Form.
  • All surgeries must be approved by the Medical Advisory Board (MAB) Exclusion Criteria:• Patient has less than 6 mm of disc height.
  • Patient has had prior lumbar spine surgery (nucleoplasty at non-index level is considered acceptable).
  • Patient has had spinal fusion in the lumbar or thoracic intervertebral spaces. Cervical fusion is allowed as long as there are no neurologic deficits in the lower extremities.
  • Patient has spondyloarthropathy or other spondylolisthesis greater than 2 mm.
  • Patient has congenital moderate or severe spinal stenosis or epidural lipomatosis.• Patient has significant facet disease. Significant is defined as pain improvement of 80% or more following image-guided medial branch blocks of the target level according to SIS guidelines (diagnostic, contrast controlled).
  • Patient has any known active malignancy.
  • Patient has previously undergone or currently on immunosuppressive therapy. Steroids used to treat inflammation are allowed.
  • Patient has active or local systemic infection.
  • Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other autoimmune disease including AIDS, ARC and HIV.
  • Patient has diabetes mellitus (Type 1 or 2) requiring daily insulin management.
  • Patient has osteopenia of the spine (T-score of -1.0 or lower). A DEXA scan should be performed to rule out patients considered at risk for osteopenia.• Patient has morbid obesity defined as a body mass index (BMI) more than 40 or a weight of more than 45 kg (100 lbs.) over ideal body weight.
  • Patient has a known allergy to silicone or barium sulfate.
  • Patient has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.
  • Patient has a significant Schmorl's node in the level to be treated. Significant is defined as a large, rectangular or irregular shaped node that has an associated active inflammatory process (Modic I changes).
  • Patient has motion of less than 3 degrees on pre-operative lateral flexion/extension radiographs.
  • Patient belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally disabled, prisoner, chronic alcohol/ substance abuser)

Intraoperative Exclusion Criteria:

  • Protrusion of the 20A Imaging Balloon up to or beyond the outer margin of the vertebra during the imaging steps.
  • Patient has a violated endplate as determined by imaging balloons during fluoroscopy.
  • Patient has a disc space that is too narrow for implantation.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05508360


Contacts
Layout table for location contacts
Contact: Andy Murillo 1 (210) 632-5444 amurillo@sstspine.com
Contact: Molly Bond 1 (715) 577-7527 mbond@sstspine.com

Locations
Layout table for location information
Colombia
CIGE: Centro de Imunologia y Genetica Recruiting
Medellín, Antioquia, Colombia
Contact: Julian Zuluaga, M.D.         
Principal Investigator: Julian Zuluaga, M.D.         
Fundacion Hospitalaria San Vicente de Paul Recruiting
Medellín, Antioquia, Colombia
Contact: Alejandra Mazo       alejandra.mazo@sanvicentsfundacion.com   
Principal Investigator: Eloy Barrios, MD         
Cediul S.A. Recruiting
Barranquilla, Atlantico, Colombia
Contact: Yolanda Muvdi       eclinicos2@cediul.com   
Principal Investigator: Salvador Mattar, MD         
Fundación Campbell Active, not recruiting
Barranquilla, Atlantico, Colombia
Sabbag Radiólogos S.A. Active, not recruiting
Barranquilla, Atlantico, Colombia
Sociedad de Cirugia de Bogota- Hospital de San Jose Recruiting
Bogotá, D.c., Colombia
Contact: Laura Alvarado       Coordinacionestudios@hospitalsanjose.org   
Principal Investigator: Rodolfo Paez, MD         
Clínica Imbanaco de Cali S.A. Recruiting
Cali, Valle Del Cauca, Colombia
Contact: Monica Dominguez       monica.dominguez@imbanaco.com   
Principal Investigator: Eduardo Walteros, MD         
Paraguay
Sanatario Americano Recruiting
Asunción, Paraguay, 1101
Contact: Carlos Cetraro       radiosolutionspy@gmail.com   
Principal Investigator: Francisco Duarte, MD         
Sponsors and Collaborators
Spinal Stabilization Technologies
Investigators
Layout table for investigator information
Study Chair: Jeff Golan, MD Jewish General Hospital
Study Chair: Michael Hess, MD London Spine Clinic/ATOS-Klinik
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Spinal Stabilization Technologies
ClinicalTrials.gov Identifier: NCT05508360    
Other Study ID Numbers: LOPAIN2
First Posted: August 19, 2022    Key Record Dates
Last Update Posted: February 10, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Spinal Stabilization Technologies:
Degenerative Disc Disease
DDD
Chronic Low Back Pain
cLBP
 Disc Herniation
Nucleus Replacement
Low Back Pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Intervertebral Disc Degeneration
Back Pain
Low Back Pain
Pain
 Neurologic Manifestations
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases